Veracyte (VCYT) Common Equity (2012 - 2026)

Veracyte has disclosed Common Equity across 15 years of filings, most recently posting $1.4 billion for Q2 2026.

• In Q2 2026, Common Equity rose 13.71% year-over-year to $1.4 billion; the TTM figure through Jun 2026 stood at $1.4 billion (up 13.71% YoY), while the FY2025 annual figure was $1.3 billion, up 11.36% from the prior year.
• Common Equity came in at $1.4 billion for Q2 2026 at Veracyte, up from $1.3 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.4 billion in Q2 2026 to a low of $1.0 billion in Q4 2023.
• Average Common Equity over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Common Equity decreased 5.32% in 2022 and grew 13.71% in 2026.
• Over 5 years, Common Equity stood at $1.1 billion in 2022, then retreated by 2.89% to $1.0 billion in 2023, then grew by 12.63% to $1.2 billion in 2024, then gained by 11.36% to $1.3 billion in 2025, then rose by 6.02% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.4 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.3 billion in Q4 2025.